TLR2 activation causes no morbidity or cardiovascular failure, despite excessive systemic nitric oxide production
Author(s) -
Anje Cauwels,
Benjamin Vandendriessche,
Jennyfer Bultinck,
Benedicte Descamps,
Elke Rogge,
Tom Van Nieuwenhuysen,
Magdalena Sips,
Christian Vanhove,
Peter Brouckaert
Publication year - 2013
Publication title -
cardiovascular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.774
H-Index - 219
eISSN - 1755-3245
pISSN - 0008-6363
DOI - 10.1093/cvr/cvt168
Subject(s) - nitric oxide , septic shock , shock (circulatory) , medicine , nitric oxide synthase , vasodilation , systemic inflammation , intensive care , systemic reaction , blood pressure , pharmacology , sepsis , inflammation , immunology , intensive care medicine , allergy
Septic shock is the leading cause of death in intensive care units worldwide, resulting from a progressive systemic inflammatory reaction causing cardiovascular and organ failure. Nitric oxide (NO) is a potent vasodilator and inhibition of NO synthases (NOS) can increase blood pressure in septic shock. However, NOS inhibition does not improve outcome, on the contrary, and certain NO donors may even provide protection. In addition, NOS produce superoxide in case of substrate or cofactor deficiency or oxidation. We hypothesized that excessive systemic iNOS-derived NO production is insufficient to trigger cardiovascular failure and shock.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom